Navigation Links
Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Bladder Cancer Litigation
Date:7/21/2013

New York, New York (PRWEB) July 21, 2013

Actos lawsuit claims involving allegations that the drug caused users to develop bladder cancer continue to move forward in a multidistrict litigation now underway in U.S District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, the Actos bladder cancer litigation’s next Status Conference has been scheduled for Thursday, July 25th. An update issued by the U.S. Judicial Panel on Multidistrict Litigation on July 10th indicated that more than 2,400 Actos lawsuits are now pending in the consolidated proceeding. (In re: Actos Product Liability Litigation, MDL No. 2299)

“We continue to hear from individuals seeking to file Actos lawsuits that allege the drug caused their bladder cancer. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed the disease after using the medication for an extended period of time

Actos Bladder Cancer Lawsuits
Actos lawsuits pending in the Western District of Louisiana accuse Takeda Pharmaceuticals of concealing knowledge that use of the type 2 diabetes treatment was associated with an increased risk of bladder cancer, and failing to provide adequate warnings to patients and doctors regarding this risk. According to court documents, the first trial in the federal Actos litigation is scheduled to begin on January 27, 2014.

In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four yea
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named ... Retail Federation, the largest retail trade association in the world, for her “advocacy and ... be named as such. According to the NRF’s website, Retail Champions are “Main Street ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, the STASH ... STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured ... tried-and-true products that have stood the test of time. These include lighting products, ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s ... biggest day each year is the Super Bowl. In the two weeks that separate the ... the host venue. The 2016 Super Bowl game will mark the 50th time it has ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... Acute non-variceal gastrointestinal bleeding accounts for approximately 20% ... Although endoscopy has been used as a first-line ... intervention can be used as a safe diagnostic ... that is refractory to endoscopic treatment. The incidence ...
... type of cellular adaptor protein and transcriptional co-activator. In ... overexpressed and highly activated in hepatic cancers and mammary ... of the inhibitor of apoptotic protein (IAP) family, which ... cell protease receptor-1 in the human genomic library in ...
... , MENLO PARK, Calif., Sept. 16 ... the development of biotherapeutic and pharmaceutical products, announced today that ... Kit for rapid detection of anti-drug antibodies (ADA) for use ... life science researchers with new levels of throughput, speed and ...
... , ST. PETERSBURG, Fla., Sep. 16 ... announced today the launch of eMed-Trac, a live instant tracking ... impairments, or children who need to be closely supervised by ... , The eMed-Trac device operates through global ...
... , , BRAINTREE, Mass. and ... HAE ) announced today that it has signed a ... a cooperative of community blood centers. The contract provides ... of innovative blood management software products, including Prelude and Interlude, ...
... trigger the neurodegenerative disease, study finds , TUESDAY, Sept. ... in regular contact with pesticides may be at increased ... Researchers asked 519 Parkinson,s patients and 511 people without ... toxins, including pesticides and solvents. Working in agriculture, education, ...
Cached Medicine News:Health News:ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies 2Health News:World's First Emergency Medical Information Franchise Launches GPS Tracking Device 2Health News:World's First Emergency Medical Information Franchise Launches GPS Tracking Device 3Health News:World's First Emergency Medical Information Franchise Launches GPS Tracking Device 4Health News:Haemonetics Signs Comprehensive Agreement with Blood Centers of America 2Health News:Pesticides Linked to Parkinson's 2
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ) ... and managing director of Warburg Pincus LLC, to the Amgen ... welcome Fred Hassan and the deep, global experience ... said Robert A. Bradway , chairman and chief executive ... innovation will serve Amgen well." Mr. Hassan has ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... Anti-IL-2 receptor antibody significantly reduced the number ... data to be submitted,for presentation at upcoming ... Calif., March 12, 2007,/PRNewswire-FirstCall/ -- Biogen Idec, ... that the ongoing CHOICE trial, a Phase ...
... (OTC Pink,Sheets:GMED), the Next Generation Disease Management company ... a,case report of a sickle cell patient whose ... GenoMed's treatment., The patient is a middle-aged African ... every day to tolerate the pain,of her sickle ...
Cached Medicine Technology:Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5GenoMed Prevents Sickle Cell Pain for Over a Year 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: